Nivolumab Plus Brentuximab Vedotin With or Without Bendamustine in Children, Adolescents, and Young Adults With R/R Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Nivolumab, Brentuximab Vedotin, +/- Bendamustine For R/R Hodgkin Lymphoma in Children, Adolescents, and Young Adults
Blood 2022 Dec 23;[EPub Ahead of Print], P Harker-Murray, C Mauz-Körholz, TM Leblanc, M Mascarin, G Michel, S Cooper, A Beishuizen, KJ Leger, L Amoroso, S Buffardi, C Rigaud, BS Hoppe, JM Lisano, S Francis, M Sacchi, PD Cole, RA Drachtman, KM Kelly, S DawFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.